MX2015005102A - Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. - Google Patents
Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.Info
- Publication number
- MX2015005102A MX2015005102A MX2015005102A MX2015005102A MX2015005102A MX 2015005102 A MX2015005102 A MX 2015005102A MX 2015005102 A MX2015005102 A MX 2015005102A MX 2015005102 A MX2015005102 A MX 2015005102A MX 2015005102 A MX2015005102 A MX 2015005102A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- subject
- reduction
- methods
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716867P | 2012-10-22 | 2012-10-22 | |
| US201361822752P | 2013-05-13 | 2013-05-13 | |
| US201361839750P | 2013-06-26 | 2013-06-26 | |
| US201361839743P | 2013-06-26 | 2013-06-26 | |
| PCT/US2013/066228 WO2014066419A2 (en) | 2012-10-22 | 2013-10-22 | Methods for reducing risks associated with heart failure and factors associated therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005102A true MX2015005102A (es) | 2016-02-09 |
Family
ID=50545459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005102A MX2015005102A (es) | 2012-10-22 | 2013-10-22 | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20150246092A1 (https=) |
| EP (5) | EP2908839B1 (https=) |
| JP (3) | JP2016503397A (https=) |
| KR (1) | KR20160009008A (https=) |
| CN (2) | CN105050613A (https=) |
| AU (2) | AU2013334788A1 (https=) |
| BR (1) | BR112015009072A2 (https=) |
| CA (1) | CA2889155A1 (https=) |
| ES (1) | ES3058737T3 (https=) |
| MX (1) | MX2015005102A (https=) |
| NI (1) | NI201500057A (https=) |
| PE (1) | PE20151434A1 (https=) |
| WO (1) | WO2014066419A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CN110339339A (zh) | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA3020393A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| WO2017223533A1 (en) * | 2016-06-24 | 2017-12-28 | University Of Southern California | Mentsh analogs as therapeutics for diabetes, obesity, and their associated diseases and complications |
| KR20200012823A (ko) * | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| CA3087699A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| KR102546547B1 (ko) | 2018-01-11 | 2023-06-22 | 삼성전자주식회사 | 보행 보조 방법 및 장치 |
| KR20220052561A (ko) | 2020-10-21 | 2022-04-28 | 장영진 | 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| CN120329388B (zh) * | 2025-04-30 | 2025-09-26 | 中日友好医院(中日友好临床医学研究所) | 一种双靶点多肽及其在心衰治疗中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| EP1890153A1 (en) * | 2006-08-16 | 2008-02-20 | F. Hoffman-la Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| EP1890154B1 (en) * | 2006-08-16 | 2012-07-04 | F. Hoffmann-La Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| US20080318909A1 (en) * | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| DK2262520T3 (en) * | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| EP2485749A4 (en) * | 2009-10-05 | 2013-07-24 | Univ Cornell | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| WO2011066374A2 (en) * | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| CN103751763A (zh) * | 2009-12-31 | 2014-04-30 | 康肽德生物医药技术有限公司 | 用于预防或治疗血管阻塞损伤的方法 |
| EP3266462A1 (en) * | 2009-12-31 | 2018-01-10 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| EP3332795A1 (en) * | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3375449A1 (en) * | 2010-03-15 | 2018-09-19 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| HK1210953A1 (en) * | 2012-08-02 | 2016-05-13 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
| EP2928562A4 (en) * | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| WO2014210062A1 (en) * | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods for the regulation of matrix metalloproteinase expression |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
-
2013
- 2013-10-22 AU AU2013334788A patent/AU2013334788A1/en not_active Abandoned
- 2013-10-22 WO PCT/US2013/066228 patent/WO2014066419A2/en not_active Ceased
- 2013-10-22 EP EP13849406.7A patent/EP2908839B1/en active Active
- 2013-10-22 CN CN201380067076.XA patent/CN105050613A/zh active Pending
- 2013-10-22 MX MX2015005102A patent/MX2015005102A/es unknown
- 2013-10-22 JP JP2015539720A patent/JP2016503397A/ja active Pending
- 2013-10-22 KR KR1020157013559A patent/KR20160009008A/ko not_active Ceased
- 2013-10-22 EP EP21197102.3A patent/EP4005582A1/en not_active Withdrawn
- 2013-10-22 EP EP25219700.9A patent/EP4711005A3/en active Pending
- 2013-10-22 EP EP24159638.6A patent/EP4397314B1/en active Active
- 2013-10-22 CN CN201910384895.6A patent/CN110193077A/zh active Pending
- 2013-10-22 US US14/437,325 patent/US20150246092A1/en not_active Abandoned
- 2013-10-22 PE PE2015000538A patent/PE20151434A1/es not_active Application Discontinuation
- 2013-10-22 ES ES24159638T patent/ES3058737T3/es active Active
- 2013-10-22 EP EP19185584.0A patent/EP3586862B1/en active Active
- 2013-10-22 BR BR112015009072A patent/BR112015009072A2/pt not_active IP Right Cessation
- 2013-10-22 CA CA2889155A patent/CA2889155A1/en not_active Abandoned
-
2015
- 2015-04-22 NI NI201500057A patent/NI201500057A/es unknown
-
2018
- 2018-02-06 JP JP2018018942A patent/JP2018109012A/ja active Pending
- 2018-07-19 AU AU2018206766A patent/AU2018206766A1/en not_active Abandoned
-
2019
- 2019-06-04 JP JP2019104270A patent/JP2019194193A/ja active Pending
- 2019-12-20 US US16/724,076 patent/US20200360462A1/en not_active Abandoned
-
2022
- 2022-06-13 US US17/838,766 patent/US20230190859A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,542 patent/US20250255929A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4711005A3 (en) | 2026-04-22 |
| EP2908839A2 (en) | 2015-08-26 |
| JP2019194193A (ja) | 2019-11-07 |
| ES3058737T3 (en) | 2026-03-12 |
| EP3586862B1 (en) | 2021-12-08 |
| CN110193077A (zh) | 2019-09-03 |
| CN105050613A (zh) | 2015-11-11 |
| JP2018109012A (ja) | 2018-07-12 |
| KR20160009008A (ko) | 2016-01-25 |
| US20230190859A1 (en) | 2023-06-22 |
| EP2908839B1 (en) | 2019-08-21 |
| PE20151434A1 (es) | 2015-10-16 |
| EP3586862A1 (en) | 2020-01-01 |
| AU2018206766A1 (en) | 2018-08-09 |
| HK1213799A1 (en) | 2016-07-15 |
| WO2014066419A2 (en) | 2014-05-01 |
| EP4397314A1 (en) | 2024-07-10 |
| EP2908839A4 (en) | 2016-06-15 |
| WO2014066419A3 (en) | 2014-06-12 |
| US20200360462A1 (en) | 2020-11-19 |
| US20150246092A1 (en) | 2015-09-03 |
| BR112015009072A2 (pt) | 2017-07-04 |
| JP2016503397A (ja) | 2016-02-04 |
| EP4711005A2 (en) | 2026-03-18 |
| EP4005582A1 (en) | 2022-06-01 |
| AU2013334788A1 (en) | 2015-06-04 |
| EP4397314B1 (en) | 2025-12-03 |
| NI201500057A (es) | 2015-07-16 |
| US20250255929A1 (en) | 2025-08-14 |
| CA2889155A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005102A (es) | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| CY1126074T1 (el) | Περιοχες gla ως παραγοντες στοχευσης | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CU20150119A7 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| EP4272757A3 (en) | Modified nk-92 cells for treating cancer | |
| AR088044A1 (es) | Proteinas de fusion para tratar trastornos metabolicos | |
| NZ630009A (en) | Angiogenesis using placental stem cells | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| CR20190034A (es) | INHIBIDORES DE GLUCOSILCERAMIDA SINTASA (Divisional 2013-0471) | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| AR095555A1 (es) | Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf) | |
| DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
| MX2017005186A (es) | Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas. | |
| UY35438A (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| CO6430497A2 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
| EA202191728A1 (ru) | Комбинированная терапия arm и естественными клетками-киллерами | |
| EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
| PH12015502037A1 (en) | Activating adiponectin by casein hydrolysate | |
| BR112016028561A2 (pt) | composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo. | |
| AR080933A1 (es) | Tratamiento de esclerosis multiple con masitinib | |
| MX2021011598A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| CO2017001899A2 (es) | Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía |